Navigation Links
Omeros Corporation Reports Third Quarter 2013 Financial Results
Date:11/7/2013

SEATTLE, Wash., Nov. 7, 2013 /PRNewswire/ --

  • Received $17.4 million in cash in October 2013
  • Total operating expenses in 3Q 2013 were $13.6 million including $3.2 million in non-cash expenses compared to $13.3 million including non-cash expenses of $2.1 million in 2Q 2013
  • U.S. and European regulators accepted Omeros' OMS302 marketing applications for review
  • OMS824 and OMS721 Phase 1 clinical programs generated positive data
  • Increased the number of unlocked orphan GPCRs to 52
  • Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the third quarter of 2013.

    "Throughout the third quarter of 2013, we continued to make significant strides in development across our pipeline," stated Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "For OMS302, the marketing applications were accepted for review by both the FDA and EMA, and the market launch is planned for the second half of 2014. Our OMS824 program for the treatment of cognitive disorders was granted orphan drug designation by the FDA, generated positive Phase 1 clinical trial results, began enrollment in a Phase 2 trial in patients with schizophrenia and is now initiating a Phase 2 trial in Huntington's disease. OMS721, our MASP-2 inhibitor, entered a Phase 1 clinical trial from which we reported positive data today, and a Phase 2 trial to evaluate the molecule's efficacy and safety in patients with thrombotic microangiopathies is planned for early 2014. Preclinically, our GPCR platform continued to identify functionally active compounds against an
    '/>"/>

    SOURCE Omeros Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock
    2. Omeros to Present at the 12th Annual Needham Healthcare Conference
    3. Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
    4. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
    5. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
    6. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
    7. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
    8. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
    9. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2014 Financial Results
    10. Attention Amarin Corporation plc Investors: Amarin Corporation plc Misled Investors According to a Newly Filed Class Action
    11. General Patent Corporation Chairman and CEO Alexander Poltorak Joins Spherix Board Industry veteran and authority on patent law and valuation joins Spherix as director
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/31/2014)... Brady (NYSE:BRC), a global leader in product and ... testimonial on the effectiveness of its FreezerBondz™ specimen ... the BloodCenter of Wisconsin discusses the challenges she faces ... thousands of samples, and how the durability of Brady’s ... design our label materials with the harsh conditions of ...
    (Date:10/30/2014)... (PRWEB) October 30, 2014 The report ... Chemicals), by Application (Cosmetics & Toiletries, and Soaps & ... to 2019”, has defined and segmented the Fragrance Ingredients ... trends in terms of value. The market has been ... North America, Europe, Asia-Pacific, Latin America, and Rest of ...
    (Date:10/30/2014)... 30, 2014 On October 26th ... Showcase in Chicago, leading applied stem cell research ... Wade McKenna presented talks on New Techniques for ... Applications For Stem Cells. , Dr. Riordan focused ... the properties of AlphaGEMS that include: wound healing; ...
    (Date:10/30/2014)... 30, 2014 Whitehouse Laboratories has formally ... Stability Testing and Package Test Capacity. Responding to growing ... a dramatic increase in environmental chamber storage space that ... and aging samples to be securely held on site ... capital expenditure has already taken place with the recent ...
    Breaking Biology Technology:Brady Debuts New Lab Label Testimonial Video 2Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 2Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 3Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 4Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 5Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 2Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 3Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 4Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 3
    ... two months ahead of schedule ... -, - Progress continues on LymphoStat-B, ABthrax and TRAIL receptor antibody ... programs - ... ROCKVILLE, Md., Nov. 1 Human Genome Sciences,Inc. (Nasdaq: HGSI ) today announced financial results ...
    ... CA -- Make way for the real nanopod and ... of researchers with the U.S. Department of Energys Lawrence ... California at Berkeley have created the first fully functional ... by several orders of magnitude the smallest radio ever ...
    ... - Dragon Pharmaceutical Inc.,(TSX: DDD; OTCBB: DRUG; ... method,for 7ACA production has been successfully implemented ... achievement validates the Company,s research,and development efforts ... bring immediate benefits to production operations by,increasing ...
    Cached Biology Technology:Human Genome Sciences Announces Third Quarter 2007 Financial Results and Key Developments 2Human Genome Sciences Announces Third Quarter 2007 Financial Results and Key Developments 3Human Genome Sciences Announces Third Quarter 2007 Financial Results and Key Developments 4Human Genome Sciences Announces Third Quarter 2007 Financial Results and Key Developments 5Human Genome Sciences Announces Third Quarter 2007 Financial Results and Key Developments 6Human Genome Sciences Announces Third Quarter 2007 Financial Results and Key Developments 7Human Genome Sciences Announces Third Quarter 2007 Financial Results and Key Developments 8Human Genome Sciences Announces Third Quarter 2007 Financial Results and Key Developments 9Make way for the real nanopod 2Make way for the real nanopod 3Make way for the real nanopod 4Dragon Announces R&D Achievement in Biotech Manufacturing Process 2Dragon Announces R&D Achievement in Biotech Manufacturing Process 3
    (Date:10/29/2014)... New research presented at the Society for Integrative ... showed for the first time that it is ... a readily available nutritional supplement, AHCC. ... A. Smith, Pharm.D., associate professor in the Department ... University of Texas Health Science Center at Houston ...
    (Date:10/29/2014)... to make their food, but they also need protection from ... a group of molecules in plants that shields them from ... of the American Chemical Society , one team reports on ... Timothy Zwier and colleagues at Purdue University note that the ... serious damage to plant DNA and, as a result, hinder ...
    (Date:10/29/2014)... a ceremony held in New York City on September ... the American Cancer Society Professor of Genome Sciences and ... 2008 Honorary Doctor of Philosophy of Tel Aviv University, ... Medical Science. , In addition to her honorary degree ... at the TAU School of Medicine, and for the ...
    Breaking Biology News(10 mins):HPV infections in women eradicated by AHCC, Japanese mushroom extract 2Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2
    ... , No one is in a better position to monitor ... the people living there. But many scientists believe the ... is simply too great to bridge -- that native peoples ... But now, researchers led by Stanford ecologist Jose Fragoso have ...
    ... New research from the Universities of Portsmouth and Leicester has ... London as being part of a giant pterosaur ... and toothed animals. Dr David Martill from the University ... Leicester examined the fossil - which consisted of the tip ...
    ... eyes or legs, yet they are able to "see" and ... is controlled by a series of molecular-level signals between proteins ... The Plant Cell, University of Missouri scientists report ... plays in this molecular signaling pathway that regulates phototropism in ...
    Cached Biology News:Can indigenous peoples be relied on to gather reliable environmental data? 2Can indigenous peoples be relied on to gather reliable environmental data? 3Tiny fossil fragment reveals giant-but-ugly-truth 2Tiny fossil fragment reveals giant-but-ugly-truth 3Protein plays role in helping plants see light 2
    IC50: 3 ng/ml · Limit of detection: 0.9 ng/ml...
    Request Info...
    Image Analysis Software. PC Version of NIH Image....
    ... the premium quality siRNAs you need for ... be readily ordered online by providing either ... providing the sense and antisense siRNA sequences. ... Silencer Pre-designed siRNAs, which are already designed ...
    Biology Products: